The main advantage of proton therapy is its precision. Protons deposit most of their energy directly in the tumor with little ...
Salvage Reirradiation for Locally Recurrent Prostate Cancer: Results From a Prospective Study With 7.2 Years of Follow-Up We investigated the SEER-Medicare linked database, identifying patients with ...
The National Association for Proton Therapy (NAPT), the nation's leading organization dedicated to increasing patient access to advanced cancer treatments, convened more than 70 national speakers to ...
The investigators note that the lower rate of feeding-tube placement with IMPT at the end of treatment, combined with a ...
A new phase III clinical trial finds that intensity-modulated radiation therapy (IMRT) and proton beam therapy resulted in similar quality-of-life outcomes and low rates of side effects for people ...
People with low- and intermediate-risk prostate cancer treated with either of two types of contemporary radiation therapy - proton beam therapy or intensity modulated radiation therapy (IMRT) - ...
SAN FRANCISCO, September 29, 2025 — A new phase III clinical trial finds that intensity-modulated radiation therapy (IMRT) and proton beam therapy resulted in similar quality-of-life outcomes and low ...
Patient-reported quality of life (QoL) was similar between proton beam therapy (PBT) and intensity-modulated radiation therapy (IMRT) among men with localized prostate cancer, the randomized PARTIQoL ...
The first randomized trial to compare proton therapy with conventional radiotherapy has not found a difference in toxicity, which is the main claim for superiority of proton therapy. The trial was ...
With smaller radiation beams, intensity-modulated radiation therapy “takes precision to the next level” for patients with prostate, an expert told CURE®. Intensity-modulated radiation therapy (IMRT) — ...
NEW YORK (Reuters Health) - A new study of an intensive and expensive form of prostate cancer therapy finds that doctors who stand to profit from the treatment are twice as likely to recommend it, ...
Of the 300 patients in the PARCER trial, 93 faced grades ≥2 adverse events (3D-CRT = 59, IG-IMRT = 34). Patients in the 3D-CRT and IG-IMRT arms spent an average of 2.39 years and 1.96 years in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results